Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
Seyed-Mohammad Reza Hashemian,Rasoul Aliannejad,Morteza Zarrabi,Masoud Soleimani,Masoud Soleimani,Massoud Vosough,Seyedeh-Esmat Hosseini,Seyedeh-Esmat Hosseini,Hamed Hossieni,Saeid Heidari Keshel,Zeinab Naderpour,Ensiyeh Hajizadeh-Saffar,Elham Shajareh,Hamidreza Jamaati,Mina Soufizomorrod,Naghmeh Khavandgar,Hediyeh Alemi,Aliasghar Karimi,Neda Pak,Negin Hossieni Rouzbahani,Negin Hossieni Rouzbahani,Masoumeh Nouri,Majid Sorouri,Ladan Kashani,Hoda Madani,Nasser Aghdami,Mohammad Vasei,Hossein Baharvand,Hossein Baharvand +28 more
TLDR
In this article, the safety, feasibility, and tolerability of the multiple infusions of high dose MSCs, which originated from the placenta and umbilical cord, in critically ill COVID-19-induced ARDS patients were presented.Abstract:
Acute respiratory distress syndrome (ARDS) is a fatal complication of coronavirus disease 2019 (COVID-19). There are a few reports of allogeneic human mesenchymal stem cells (MSCs) as a potential treatment for ARDS. In this phase 1 clinical trial, we present the safety, feasibility, and tolerability of the multiple infusions of high dose MSCs, which originated from the placenta and umbilical cord, in critically ill COVID-19-induced ARDS patients. A total of 11 patients diagnosed with COVID-19-induced ARDS who were admitted to the intensive care units (ICUs) of two hospitals enrolled in this study. The patients were critically ill with severe hypoxemia and required mechanical ventilation. The patients received three intravenous infusions (200 × 106 cells) every other day for a total of 600 × 106 human umbilical cord MSCs (UC-MSCs; 6 cases) or placental MSCs (PL-MSCs; 5 cases). There were eight men and three women who were 42 to 66 years of age. Of these, six (55%) patients had comorbidities of diabetes, hypertension, chronic lymphocytic leukemia (CLL), and cardiomyopathy (CMP). There were no serious adverse events reported 24–48 h after the cell infusions. We observed reduced dyspnea and increased SpO2 within 48–96 h after the first infusion in seven patients. Of these seven patients, five were discharged from the ICU within 2–7 days (average: 4 days), one patient who had signs of acute renal and hepatic failure was discharged from the ICU on day 18, and the last patient suddenly developed cardiac arrest on day 7 of the cell infusion. Significant reductions in serum levels of tumor necrosis factor-alpha (TNF-α; P < 0.01), IL-8 (P < 0.05), and C-reactive protein (CRP) (P < 0.01) were seen in all six survivors. IL-6 levels decreased in five (P = 0.06) patients and interferon gamma (IFN-γ) levels decreased in four (P = 0.14) patients. Four patients who had signs of multi-organ failure or sepsis died in 5–19 days (average: 10 days) after the first MSC infusion. A low percentage of lymphocytes (< 10%) and leukocytosis were associated with poor outcome (P = 0.02). All six survivors were well with no complaints of dyspnea on day 60 post-infusion. Radiological parameters of the lung computed tomography (CT) scans showed remarkable signs of recovery. We suggest that multiple infusions of high dose allogeneic prenatal MSCs are safe and can rapidly improve respiratory distress and reduce inflammatory biomarkers in some critically ill COVID-19-induced ARDS cases. Patients that develop sepsis or multi-organ failure may not be good candidates for stem cell therapy. Large randomized multicenter clinical trials are needed to discern the exact therapeutic potentials of MSC in COVID-19-induced ARDS.read more
Citations
More filters
Journal ArticleDOI
Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era.
Ángel Serrano-Aroca,Kazuo Takayama,Alberto Tuñón-Molina,Murat Seyran,Sk. Sarif Hassan,Pabitra Pal Choudhury,Vladimir N. Uversky,Kenneth Lundstrom,Parise Adadi,Giorgio Palù,Alaa A. A. Aljabali,Gaurav Chauhan,Ramesh Kandimalla,Murtaza M. Tambuwala,Amos Lal,Tarek Mohamed Abd El-Aziz,Tarek Mohamed Abd El-Aziz,Samendra P. Sherchan,Debmalya Barh,Elrashdy M. Redwan,Nicolas G. Bazan,Yogendra Kumar Mishra,Bruce D. Uhal,Adam Brufsky +23 more
TL;DR: In this article, the authors evaluated the antiviral activity and broad-spectrum antimicrobial properties of carbon-based nanomaterials (CBNs), such as fullerene, carbon dots, graphene, and their derivatives.
Journal ArticleDOI
Stem cell-based therapy for human diseases
Duc Manh Hoang,Phuong Tran Pham,T. Q. Bach,Anh T L Ngo,Q. T. Nguyen,Trang Phan,Giang H. Nguyen,Phuong T. Le,Van T. Hoang,Nicholas R. Forsyth,Michael Heke,Liem T. Nguyen +11 more
TL;DR: In this article , a review provides an update on recent clinical applications using either human pluripotent stem cells (hPSCs) or MSCs derived from bone marrow (BM), adipose tissue (AT), or the umbilical cord (UC) for the treatment of human diseases, including neurological disorders, pulmonary dysfunctions, metabolic/endocrine-related diseases, reproductive disorders, skin burns, and cardiovascular conditions.
Journal ArticleDOI
Cell therapy in patients with COVID-19 using Wharton's jelly mesenchymal stem cells: a phase 1 clinical trial.
Mahshid Saleh,Amir Abbas Vaezi,Rasoul Aliannejad,Amir Ali Sohrabpour,Seyedeh Zahra Fotook Kiaei,Mahdi Shadnoush,Vahid Siavashi,Leila Aghaghazvini,Batoul Khoundabi,Shahriyar Abdoli,Bahram Chahardouli,Iman Seyhoun,Neda Alijani,Javad Verdi +13 more
TL;DR: In this article, the safety and efficacy of injecting intravenous Wharton's jelly-derived mesenchymal stem cells (MSC) in patients with COVID-19 as a treatment was evaluated.
Journal ArticleDOI
Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice.
TL;DR: In this paper, the advantages and disadvantages of using autologous vs. allogeneic mesenchymal stem/stromal cell (MSC)-based therapeutics are discussed.
Journal ArticleDOI
Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot study
Ying-gang Zhu,Meng-Meng Shi,Antoine Monsel,Chengxiang Dai,X Dong,Hong Hua Shen,Suke Li,Jing Chang,Cuili Xu,Ping Li,Jing Wang,Meiting Shen,Cheng-jie Ren,Dezhong Chen,Jieming Qu +14 more
TL;DR: In this paper , the safety and efficiency of aerosol inhalation of the exosomes derived from human adipose-derived MSCs (haMSC-Exos) in patients with COVID-19 was explored.
References
More filters
Journal ArticleDOI
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
TL;DR: The epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of patients with laboratory-confirmed 2019-nCoV infection in Wuhan, China, were reported.
Journal ArticleDOI
A Novel Coronavirus from Patients with Pneumonia in China, 2019.
Na Zhu,Dingyu Zhang,Wenling Wang,Xingwang Li,Bo Yang,Jingdong Song,Xiang Zhao,Baoying Huang,Weifeng Shi,Roujian Lu,Peihua Niu,Faxian Zhan,Xuejun Ma,Dayan Wang,Wenbo Xu,Wenbo Xu,Guizhen Wu,George F. Gao,Wenjie Tan +18 more
TL;DR: Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily, which is the seventh member of the family of coronaviruses that infect humans.
Journal ArticleDOI
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Fei Zhou,Ting Yu,Ronghui Du,Guohui Fan,Ying Liu,Zhibo Liu,Jie Xiang,Yeming Wang,Bin Song,Xiaoying Gu,Xiaoying Gu,Lulu Guan,Yuan Wei,Li Hui,Xudong Wu,Jiuyang Xu,Shengjin Tu,Yi Zhang,Hua Chen,Bin Cao +19 more
TL;DR: Wang et al. as discussed by the authors used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death, including older age, high SOFA score and d-dimer greater than 1 μg/mL.
Journal ArticleDOI
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
Dawei Wang,Bo Hu,Chang Hu,Fangfang Zhu,Xing Liu,Jing Zhang,Binbin Wang,Hui Xiang,Zhenshun Cheng,Yong Xiong,Yan Zhao,Yirong Li,Xinghuan Wang,Zhiyong Peng +13 more
TL;DR: The epidemiological and clinical characteristics of novel coronavirus (2019-nCoV)-infected pneumonia in Wuhan, China, and hospital-associated transmission as the presumed mechanism of infection for affected health professionals and hospitalized patients are described.
Journal ArticleDOI
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
Nanshan Chen,Min Zhou,Xuan Dong,Jie-Ming Qu,Fengyun Gong,Yang Han,Yang Qiu,Jingli Wang,Ying Liu,Yuan Wei,Jia'an Xia,Ting Yu,Xinxin Zhang,Li Zhang +13 more
TL;DR: Characteristics of patients who died were in line with the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia, and further investigation is needed to explore the applicability of the Mu LBSTA scores in predicting the risk of mortality in 2019-nCoV infection.
Related Papers (5)
Transplantation of ACE2 - Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia.
Zikuan Leng,Rongjia Zhu,Wei Hou,Yingmei Feng,Yanlei Yang,Qin Han,Guangliang Shan,Fanyan Meng,Dongshu Du,Shihua Wang,Junfen Fan,Wenjing Wang,Luchan Deng,Hongbo Shi,Hongjun Li,Zhongjie Hu,Fengchun Zhang,Jinming Gao,Hongjian Liu,Xiaoxia Li,Yangyang Zhao,Kan Yin,Xijing He,Zhengchao Gao,Yibin Wang,Bo Yang,Ronghua Jin,Ilia Stambler,Lee Wei Lim,Huanxing Su,Alexey Moskalev,Antonio Cano,Sasanka Chakrabarti,Kyung-Jin Min,Georgina M. Ellison-Hughes,Calogero Caruso,Kunlin Jin,Robert Chunhua Zhao +37 more
Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial.
Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Giacomo Lanzoni,E. Linetsky,Diego Correa,Shari Messinger Cayetano,Roger A. Alvarez,Dimitrios Kouroupis,Ana M. Alvarez Gil,Raffaella Poggioli,Phillip Ruiz,Antonio Marttos,Khemraj Hirani,Crystal A. Bell,Halina Kusack,Lisa E. Rafkin,David A. Baidal,Andrew Pastewski,Kunal Gawri,Clarissa Leñero,Alejandro Mantero,Sarah W. Metalonis,Xiaojing Wang,Luis Roque,Burlett Masters,Norma S. Kenyon,Enrique Ginzburg,Xiumin Xu,Jianming Tan,Arnold I. Caplan,Marilyn K. Glassberg,Rodolfo Alejandro,Camillo Ricordi +30 more
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more